Health Condition 1: C220- Liver cell carcinoma
Conditions
Interventions
Intervention1: Atezolizumab: V infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle
Control Intervention1: Lenvatinib: once a day by mouth (PO) during each 21-day cycle.
Control Intervent
Sponsors
F HoffmannLa Roche Ltd
Roche Products India Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: Locally advanced or metastatic and or unresectable HCC with diagnosis confirmed by histology or cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic patients. Disease progression following prior atezolizumab plus bevacizumab combination treatment for HCC, for at least 4 consecutive treatment cycles, and 2 subsequent tumor assessments. It is required that at least 1 tumor assessment shows either stable disease, partial response, or complete response. Child-Pugh class A within 7 days prior to randomization. ECOG Performance Status of 0 or 1 within 7 days prior to randomization. Life expectancy of at least 12 weeks. Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade less than equal to 1 prior to study entry, with the exception of alopecia.
Exclusion criteria
Exclusion criteria: Symptomatic, untreated, or actively progressing central nervous system metastases. History of leptomeningeal disease. History of hepatic encephalopathy, preceding 6 months, unresponsive to therapy within 3 days. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC. Patients receiving any TKI or PD-1/PD-L1 antibody or such combination in a previous treatment line against HCC (except atezolizumab plus bevacizumab combination). Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-cytotoxic T lymphocyte?associated protein 4 (CTLA-4), anti-PD-1, and anti-PD-L1 (other than atezolizumab) therapeutic antibodies. Patients who discontinued atezolizumab in a previous treatment line against HCC primarily for toxicity or intolerability are not eligible for the study. Patients on a liver transplantation list. Prior allogeneic stem cell or solid organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the efficacy of atezolizumab plus lenvatinib or sorafenib compared with lenvatinib or sorafenib aloneTimepoint: Tumor assessments will be performed at baseline, every 6 weeks (+1 week) for the first 54 weeks following the initiation of study treatment, and every 9 weeks (+ 1 week) thereafter, with additional scans as clinically indicated. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate patient-reported function and GHS/QoL experienced by patients receiving atezolizumab plus lenvatinib or sorafenib versus lenvatinib or sorafenib aloneTimepoint: TTD, of HRQoL, defined as the time from randomization to first deterioration (decrease from baseline of more than equal to 10 points) maintained for two consecutive assessments, or one assessment followed by death from any cause within 3 weeks (if Cycle 1-6) or 6 weeks (if after Cycle 6) in the following EORTC QLQ-C30 scales (separately): physical function, role function, and GHS/QoL;To evaluate the efficacy of atezolizumab plus lenvatinib or sorafenib compared to lenvatinib or sorafenib aloneTimepoint: Assessments per investigator according to RECIST v1.1 -Progression free survival -Confirmed objective response rate -Time to progression -Duration of response -Time to deterioration of health-related quality of life | — |
Countries
Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Costa Rica, Croatia, Egypt, Estonia, Finland, France, Germany, Greece, India, Israel, Italy, Japan, Malaysia, Philippines, Republic of Korea, Russian Federation, Saudi Arabia, Slovenia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom
Contacts
Public ContactMr Amol Pawar
Roche Products (India) Pvt. Ltd.
Outcome results
None listed